PRE-CLINICAL DEVELOPMENT OF AN IP3K INHIBITOR FOR SOLID CANCER TREATMENT (Q2035314): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Removed claims)
(‎Changed an Item: The budget was changed)
Property / budget
 
1,002,016.42 Euro
Amount1,002,016.42 Euro
UnitEuro
Property / budget: 1,002,016.42 Euro / rank
 
Normal rank
Property / EU contribution
 
500,629.91 Euro
Amount500,629.91 Euro
UnitEuro
Property / EU contribution: 500,629.91 Euro / rank
 
Normal rank
Property / co-financing rate
 
49.96 percent
Amount49.96 percent
Unitpercent
Property / co-financing rate: 49.96 percent / rank
 
Normal rank

Revision as of 09:05, 12 February 2022

Project Q2035314 in Italy
Language Label Description Also known as
English
PRE-CLINICAL DEVELOPMENT OF AN IP3K INHIBITOR FOR SOLID CANCER TREATMENT
Project Q2035314 in Italy

    Statements

    country
    Italy
    0 references
    EU contribution
    500,629.91 Euro
    0 references
    budget
    1,002,016.42 Euro
    0 references
    co-financing rate
    49.96 percent
    0 references
    start time
    13 December 2016
    0 references
    expected end time
    6 July 2019
    0 references
    beneficiary name (string)
    CNR - CONSIGLIO NAZIONALE DELLE RICERCHE
    0 references
    MENARINI RICERCHE S.P.A.
    0 references
    programme
    Lazio - ERDF
    0 references
    coordinate location

    41°40'3.11"N, 12°30'17.24"E
    0 references
    summary
    IL PROGETTO SI PROPONE LA CARATTERIZZAZIONE PRECLINICA DEL MEN1611, UN NUOVO INIBITORE DI PI3K CHE HA LA CAPACITà DI INIBIRE IN MODO PREFERENZIALE L?ISOFORMA ALFA, WILD TYPE E MUTATA. VERRANNO STUDIATI I DETERMINANTI MOLECOLARI DELLA SENSIBILITà (Italian)
    0 references
    THE PROJECT IS PROPOSED FOR THE PRE-CLINICAL CHARACTERISATION OF THE MEN1611, A NEW P3K INHIBITOR WHICH HAS THE CAPACITY TO BLOCK, IN A PREFERENTIAL MANNER, THE ALPHA, WILD, AND THE RANGE WHICH HAVE CHANGED. THE MOLECULAR DETERMINANTS OF AWARENESS WILL BE STUDIED. (English)
    0 references
    LE PROJET PROPOSE LA CARACTÉRISATION PRÉCLINIQUE DU MEN1611, UN NOUVEL INHIBITEUR PI3K CAPABLE D’INHIBER PRÉFÉRENTIELLEMENT L’ISOFORME ALPHA, DE TYPE SAUVAGE ET MUTÉ. LES DÉTERMINANTS MOLÉCULAIRES DE LA SENSIBILITÉ SERONT ÉTUDIÉS (French)
    point in time
    16 December 2021
    0 references
    HET PROJECT STELT DE PREKLINISCHE KARAKTERISERING VAN DE MEN1611 VOOR, EEN NIEUWE PI3K-REMMER DIE DE MOGELIJKHEID HEEFT OM BIJ VOORKEUR HET ALFA-ISOFORM, WILDTYPE EN GEMUTEERD TE REMMEN. MOLECULAIRE DETERMINANTEN VAN GEVOELIGHEID ZULLEN WORDEN ONDERZOCHT (Dutch)
    point in time
    23 December 2021
    0 references
    DAS PROJEKT SCHLÄGT DIE PRÄKLINISCHE CHARAKTERISIERUNG DES MEN1611 VOR, EINEM NEUEN PI3K-INHIBITOR, DER DIE FÄHIGKEIT HAT, DIE ALPHA-ISOFORM, WILDE ART UND MUTATION BEVORZUGT ZU HEMMEN. MOLEKULARE DETERMINANTEN DER SENSITIVITÄT WERDEN UNTERSUCHT (German)
    point in time
    24 December 2021
    0 references
    EL PROYECTO PROPONE LA CARACTERIZACIÓN PRECLÍNICA DEL MEN1611, UN NUEVO INHIBIDOR PI3K QUE TIENE LA CAPACIDAD DE INHIBIR PREFERENTEMENTE LA ISOFORMA ALFA, SALVAJE Y MUTADA. SE ESTUDIARÁN LOS DETERMINANTES MOLECULARES DE LA SENSIBILIDAD (Spanish)
    point in time
    25 January 2022
    0 references
    location (string)
    POMEZIA
    0 references

    Identifiers

    Italian Unique Project Code
    F57H18000070007
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q2035314&oldid=27872486"